---
layout: post
title: "Determination That K-TAB (Potassium Chloride) Extended-Release Tablets, 10 Milliequivalents and 20 Milliequivalents, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
date: 2026-02-05 18:56:21 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-16537
original_published: 2023-08-03 00:00:00 +0000
significance: 8.00
---

# Determination That K-TAB (Potassium Chloride) Extended-Release Tablets, 10 Milliequivalents and 20 Milliequivalents, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** August 03, 2023 00:00 UTC
**Document Number:** 2023-16537

## Summary

The Food and Drug Administration (FDA or Agency) has determined that K-TAB (potassium chloride) extended-release tablets, 10 milliequivalents and 20 milliequivalents, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for potassium chloride extended-release tablets, 10 milliequivalents (meqs) and 20 meqs, if all other legal and regulatory requirements are met.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/08/03/2023-16537/determination-that-k-tab-potassium-chloride-extended-release-tablets-10-milliequivalents-and-20)
- API: https://www.federalregister.gov/api/v1/documents/2023-16537

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
